【科研项目】

[1] 国家自然科学基金面上项目，基于BRD4通过c-MYC-MYH9轴调控MYH9与HIF-1α相互作用探讨BET抑制剂防治黑素瘤转移的机制研究， 2019.1-2022.12

[2] 国家自然科学基金面上项目，BRD4及其抑制剂调控HIPPO/YAP1通路防治黑素瘤增殖、侵袭及转移机制研究， 2021.10-2024.12

[3] 湖南省自然科学基金杰出青年基金项目，皮肤疾病药理学，2021.1-2023.12

[4] 国家重点研发计划子课题，老年常见皮肤病精准分型和诊断研究， 2022.12-2025.12

[5] 万州区科卫联合项目重点项目，基于AI技术的创新药物研发体系建设研究， 2023.7-2025.6

【学术成果】

[1] Deng J#, Pan T#, Lv C, Cao L, Li L, Zhou X, Li G, Li H, Vicencio JM, Xu Y, Wei F, Wang Y, Liu Z*, Zhou G*, Yin M*.  Exosomal transfer leads to chemoresistance through oxidative phosphorylation-mediated stemness phenotype in colorectal cancer. Theranostics. 2023 Sep 11; 13(14): 5057-5074. doi: 10.7150/thno.84937.（IF= 12.4）

[2] Zeng F, Li Y, Meng Y, Sun H, He Y, Yin M*, Chen X*, Deng G*. BET inhibitors synergize with sunitinib in melanoma through GDF15 suppression. Exp Mol Med. 2023 Feb, 55(2): 364-376. doi: 10.1038/s12276-023-00936-y.（IF= 12.8）

[3] Zhang M, Liu ZZ, Aoshima K, Cai WL, Sun H, Xu T, Zhang Y, An Y, Chen JF, Chan LH, Aoshima A, Lang SM, Tang Z, Che X, Li Y, Rutter SJ, Bossuyt V, Chen X, Morrow JS, Pusztai L, Rimm DL, Yin M*, Yan Q*. CECR2 drives breast cancer metastasis by promoting NF-κB signaling and macrophage-mediated immune suppression. SCI TRANSL MED. 2022 Feb 2, 14 (630): eabf5473. doi: 10.1126/scitranslmed.abf5473. （IF= 19.32）

[4] Deng G, Zeng F, He Y, Meng Y, Sun H, Su J, Zhao S, Cheng Y, Chen X*, Yin M*. EEF2K silencing inhibits tumour progression through repressing SPP1 and synergizes with BET inhibitors in melanoma. Clinical and Translational Medicine. 2022 Feb, 12(2): e722. doi: 10.1002/ctm2.722. （IF= 10.6）

[5] Chen X, Wang K, Jiang S, Sun H, Che X, Zhang M, He J, Wen Y, Liao M, Li X, Zhou X, Song J, Ren X, Yi W, Yang J, Chen X, Yin M*, Cheng Y*. eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma. J Immunother Cancer. 2022 Mar, 10(3): e004026. doi: 10.1136/jitc-2021-004026. （IF= 12.47）

[6] Li X, Zhao S, Bian X, Zhang L, Lu L, Pei S, Dong L, Shi W, Huang L, Zhang X, Chen M, Chen X*, Yin M*. Signatures of EMT, immunosuppression, and inflammation in primary and recurrent human cutaneous squamous cell carcinoma at single-cell resolution. Theranostics, 2022 Oct 31, 12(17): 7532-7549. doi: 10.7150/thno.77528. （IF= 12.4）

[7] Yin M*, Guo Y, Hu R, Cai WL, Li Y, Pei S, Sun H, Peng C, Li J, Ye R, Yang Q, Wang N, Tao Y, Chen X*, Yan Q*. Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction. Nat Commun. 2020 Apr 14, 11(1): 1833. doi: 10.1038/s41467-020-15290-0. （IF= 14.919）

[8] Deng G, Zeng F*, Zhang L*, Chen H*, Chen X*, Yin M*. Characteristics of Pregnant COVID-19 Patients with Liver Injury. J Hepatol. 2020 Oct, 73(4): 989-991. doi: 10.1016/j.jhep.2020.06.022. （IF= 25.083）

[9] Li Z#, Yin M#, Zhang H, Ni W, Pierce RW, Zhou HJ, Min W. BMX Represses Thrombin-PAR1-Mediated Endothelial Permeability and Vascular Leakage During Early Sepsis. Circ Res. 2020 Feb 14, 126(4): 471-485. doi: 10.1161/CIRCRESAHA.119.315769. （IF= 17.367）

[10] Deng G#, Zeng F#, Su J, Zhao S, Hu R, Zhu W, Hu S, Chen X*, Yin M*. BET inhibitor suppresses melanoma progression via the noncanonical NF-κB/SPP1 pathway. Theranostics. 2020 Sep 15, 10(25): 11428-11443. doi: 10.7150/thno.47432. （IF= 11.556）

【研究方向】肿瘤表观遗传学、癌症生物学、肿瘤免疫学、创新药物转化

【招生专业】生物医学工程

【联系方式】yinmingzhu2008@126.com